menu
The non-invasive cancer diagnostics market is estimated to be worth around USD 20.1 billion
The non-invasive cancer diagnostics market is estimated to be worth around USD 20.1 billion
Liquid biopsies have emerged as a versatile diagnostic solution, especially for cases when conventional (invasive) diagnostic tests are inconclusive or when the clinical condition is related to an organ that is not amenable to biopsy access

Roots Analysis is pleased to announce the publication of its recent study,titled, “Liquid Biopsy and Other Non-InvasiveCancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating TumorMarkers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers.

 

Thereport features an extensive study of the current market landscape, offering aninformed opinion on the likely adoption of this approach over the next decade.It features an in-depth analysis, highlighting the capabilities of variousstakeholders engaged in this domain. In addition to other elements, the studyincludes:

§ A detailed review ofthe overall landscape of the non-invasive cancer diagnostics market. 

§ An analysis of thevarious partnerships pertaining to non-invasive cancer diagnostics, which havebeen established between 2016 and 2019.

§ An analysis of theinvestments made in companies engaged in the development of non-invasive cancerdiagnostics.

§ An analysis of theinitiatives of big pharma players.

§ A detailedacquisition target analysis.

§ Elaborate profiles ofthe key players engaged in this domain.

§ A detailed marketforecast, featuring analysis of the current and projected future opportunity acrosskey market segments (listed below)

§ Type of Tumor Marker

§  ctDNA

§  cfDNA

§  CTCs

§  Exosomes

§  Others

 

§ Application

§  Diagnosis / Early Diagnosis

§  Patient Monitoring

§  Recurrence Monitoring

 

§ Target CancerIndication

§  Breast Cancer

§  Lung Cancer

§  Colorectal Cancer

§  Prostate Cancer

§  Bladder Cancer

§  Melanoma

§  Gastric Cancer

§  Pancreatic Cancer

§  Ovarian Cancer

§  Others

 

§ End Users

§  Hospitals

§  Research Institutes

§  Others

 

§ Key Geographical Regions 

Press Release: Variation 1 (Format 2)

 

§  North America

§  Europe

§ Asia-Pacific

§ Rest of the World

 

Key companies covered in the report:

§ Amoy Diagnostics

§ DiaCarta

§ HaploX Biotechnology

§ NeoGenomics

§ QIAGEN

§ Swift Biosciences

§ Sysmex Inostics

§ Thermo Fisher Scientific

 

Formore information, please click on the following link: 

https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html

 

Other recent offerings

1.     DNA-EncodedLibraries: Platforms and Services Market

2.     AntibodyDiscovery: Services and Platforms Market (2ndEdition), 2018-2028

3.     InSilico / Computer-Aided Drug Discovery ServicesMarket: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid,Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery,Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based DrugDiscovery, Interface Based Drug Discovery Approaches)

1.    Cancer BiomarkersMarket:Focus on TMB, MSI / MMR and TILs Testing, 2019-2030

 

About Roots Analysis

Roots Analysis is oneof the fastest growing market research companies, sharing fresh and independentperspectives in the bio-pharmaceutical industry. The in-depth research,analysis and insights are driven by an experienced leadership team which hasgained many years of significant experience in this sector. If you’d like helpwith your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots AnalysisPrivate Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com